open access

Vol 88, No 3 (2020)
LETTERS
Published online: 2020-07-18
Submitted: 2020-04-16
Accepted: 2020-05-01
Get Citation

Infliximab-induced erythema multiforme in a patient with chronic sarcoidosis

Andreas Afthinos, Aggeliki Pandi, Maria Horti, Ilias C Papanikolaou
DOI: 10.5603/ARM.2020.0131
·
Pubmed: 32706116
·
Adv Respir Med 2020;88(3):289-291.

open access

Vol 88, No 3 (2020)
LETTERS
Published online: 2020-07-18
Submitted: 2020-04-16
Accepted: 2020-05-01

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

sarcoidosis; infliximab; erythema multiforme; interstitial lung diseases

About this article
Title

Infliximab-induced erythema multiforme in a patient with chronic sarcoidosis

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 3 (2020)

Pages

289-291

Published online

2020-07-18

DOI

10.5603/ARM.2020.0131

Pubmed

32706116

Bibliographic record

Adv Respir Med 2020;88(3):289-291.

Keywords

sarcoidosis
infliximab
erythema multiforme
interstitial lung diseases

Authors

Andreas Afthinos
Aggeliki Pandi
Maria Horti
Ilias C Papanikolaou

References (10)
  1. Baughman RP, Drent M, Kavuru M, et al. Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006; 174(7): 795–802.
  2. Zhou Y, Lower EE, Li H, et al. Clinical characteristics of patients with bone sarcoidosis. Semin Arthritis Rheum. 2017; 47(1): 143–148.
  3. Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and tolerance of anti-tumor necrosis factor α agents in cutaneous sarcoidosis: a french study of 46 cases. JAMA Dermatol. 2017; 153(7): 681–685.
  4. Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Groupe Sarcoïdose Francophone. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017; 47(2): 288–294.
  5. Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol. 2017; 56(11): 1087–1102.
  6. Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol. 2017; 18(6): 771–787.
  7. STN: BL 103772/5258. Food and Drug Administration report. 0ctober. ; 29: 2009.
  8. Edwards D, Boritz E, Cowen EW, et al. Erythema multiforme major following treatment with infliximab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115(2): e36–e40.
  9. Decock A, Van Assche G, Vermeire S, et al. Sarcoidosis-Like lesions: another paradoxical reaction to anti-tnf therapy? J Crohns Colitis. 2017; 11(3): 378–383.
  10. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(1): 19–27.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl